IMPORTANT INFORMATION ABOUT UPTRAVI

• Before you take UPTRAVI, tell your healthcare provider if you have narrowing of the pulmonary veins, a condition called pulmonary veno-occlusive disease.¹

summary

Before you take UPTRAVI, tell your healthcare provider about all of your medical conditions, including if you:

• have liver problems.¹
• have narrowing of the pulmonary veins, a condition called pulmonary veno-occlusive disease.¹
• are pregnant or plan to become pregnant. It is not known if UPTRAVI will harm your unborn baby.¹
• are breastfeeding or plan to breastfeed. It is not known if UPTRAVI passes into your breast milk. You and your healthcare provider should decide if you will take UPTRAVI or breastfeed. You should not do both.¹

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. UPTRAVI and other medicines may affect each other causing side effects. Do not start any new medicine until you check with your healthcare provider.¹

Do not take UPTRAVI if you:

• take gemfibrozil because this medicine may affect how UPTRAVI works and cause side effects.¹
• are allergic to selexipag or any of the other ingredients of this medicine, including:¹
  • Inactive ingredients in UPTRAVI tablets: corn starch, D-mannitol, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, and magnesium stearate. The tablets are film coated with a coating material containing carnauba wax, hypromellose, propylene glycol, titanium dioxide, along with mixtures of iron oxide black, iron oxide red, or iron oxide yellow.
  • Inactive ingredients in UPTRAVI for injection: glycine, phosphoric acid, polysorbate 20, and sodium hydroxide.

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT INFORMATION for UPTRAVI.¹